Radius Health, Inc.
- FDA Approves Tymlos (abaloparatide) for the Treatment of Postmenopausal Women with Osteoporosis at High Risk for Fracture - April 28, 2017
- Radius Health Receives Notification of PDUFA Extension for Abaloparatide-SC - March 10, 2017
- Radius Announces FDA Acceptance for Filing of NDA for Abaloparatide-SC for the Treatment of Postmenopausal Women with Osteoporosis - May 31, 2016
- Radius Health Submits NDA to the U.S. FDA for Abaloparatide-SC for the Treatment of Postmenopausal Women with Osteoporosis - March 30, 2016
Drugs Associated with Radius Health, Inc.
Radius Health, Inc. manufactures, markets and/or distributes 1 drug in the United States. Medications listed here may also be marketed under different names in different countries. Non-US country and region specific information is not available on this page.
Generic name: abaloparatide
Drug class: parathyroid hormone and analogs
|51 reviews||4.1 / 10|
|For ratings, users were asked how effective they found the medicine while considering positive/adverse effects and ease of use (1 = not effective, 10 = most effective).|